All In MedTech

Device Trial Radar · NCT01679132

BAROSTIM NEO Hypertension Pivotal Trial

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10

Actual

Start

Apr 12, 2013

Primary completion

Jul 2025

Study completion Jul 23, 2025

Sponsor

Lead sponsor
CVRx, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 5, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).

Conditions

  • Uncontrolled Hypertension

Interventions

  • BAROSTIM NEO System and Medical ManagementDevice

    Experimental: Device and Medical Management Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess long-term adverse events in subjects implanted with the BAROSTIM NEO System.Time frame: For the duration of the study, up to ten years.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Heart Rhythm Research Center

    Phoenix, Arizona

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.